Sabby Management’s Moleculin Biotech MBRX Stock Holding History

Sabby Management’s Portfolio MBRX Stock Details MBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-75,021	Closed	-$172K	–	32
2026 Q1	$172K	Buy	+75,021	New	+$248K	0.38%	15
2017 Q2	–	Sell	-44	Closed	-$117K	–	243
2017 Q1	$117K	Buy	+44	New	+$154K	0.01%	234

Other funds holding MBRX

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Rockefeller Capital Management New York $65.2B AUM 31.44% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sabby Management's MBRX Position: Q2 2026 in Review

Sabby Management sold out of Moleculin Biotech (MBRX) in Q2 2026, closing a stake of 75,021 shares — an estimated $172K sold.

Sabby Management first reported a position in MBRX in Q1 2017 and held it in 2 quarters. The position peaked at $172K in Q1 2026. 18 funds tracked by Wall St. Rank hold MBRX as of Q2 2026.

Sabby Management reported no remaining Moleculin Biotech position as of Q2 2026 after selling out during the quarter.
Sabby Management sold 75,021 Moleculin Biotech shares in Q2 2026, an estimated $172K.
Sabby Management first reported a position in Moleculin Biotech in Q1 2017 and held it in 2 quarters.
Sabby Management's Moleculin Biotech position peaked at $172K in Q1 2026.
18 funds tracked by Wall St. Rank held Moleculin Biotech as of Q2 2026.

Based on Sabby Management's 13F filing for Q2 2026, filed 14 Aug 2026.